Xcout Intel
Coherus BioSciences
Coherus BioSciences, Inc. is a biopharmaceutical company headquartered in Redwood City, California, focused on oncology and developing innovative therapeutics.
Subscribe to see Coherus BioSciences’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Coherus BioSciences at a glance
Coherus BioSciences is a biotech company headquartered in United States. It has raised at least $126.8M across the 4 funding rounds on record. Its most recent funding round raised $6.8M in December 2017. Xcout tracks 21 named people at Coherus BioSciences, including Dennis M Lanfear (President & Chief Executive Officer). Xcout recorded 11 job postings from Coherus BioSciences in the last 90 days.
Coherus BioSciences leadership
- Dennis M LanfearPresident & Chief Executive Officer
- Bryan McMichaelChief Financial Officer
- Andy RittenbergChief Legal Officer
- Arvind SoodChief Strategy and Corporate Affairs Officer
- Rebecca SunshineChief Human Resources Officer
- Rosh Dias, M.D., M.R.C.P.Chief Medical Officer
15 more named people on record for Coherus BioSciences, with roles, board committees and tenure — see the full roster →
Coherus BioSciences funding rounds
At least $126.8M raised across the 4 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $6.8M | — | |
| SEC Form D filing | $10M | — | |
| Series C | $55M | 3 named | |
| Series A | $55M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Hiring at Coherus BioSciences
Xcout recorded 11 job postings from Coherus BioSciences in the last 90 days, from a hiring record Xcout has kept since July 2026.
The weekly hiring trend, the roles and locations behind it — see Coherus BioSciences's hiring signals →
Investors
Tech stack
Coherus BioSciences competitors
A few of Coherus BioSciences's closest competitors — see the full list of competitors and alternatives →
Trellis Bioscience, Inc. is a clinical-stage biotechnology company located in Redwood City, California, focused on developing antibody-based therapeutics.
VelosBio Inc. is a clinical-stage biopharmaceutical company based in California, United States, focused on developing novel antibody-drug conjugates to transform cancer treatment for patients.
Hinge Bio, Inc. is a privately held biotechnology company headquartered in Redwood City, California, leveraging its GEM-DIMER platform to design and develop therapeutics for cancer as well as autoimmune and inflammatory diseases.
Curon Biopharmaceutical is a clinical-stage biotechnology company developing antibody-based medicines, including bispecific antibodies, for cancer and other serious diseases. It serves patients and healthcare providers through the development of therapeutic biologics, with programs intended for oncology and immunology applications.
Revolution Medicines is a biotechnology research company headquartered in Redwood City, California. Its mission is to revolutionize treatment for patients with RAS-addicted cancers through targeted medicines, translating frontier oncology targets.
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.
Get Coherus BioSciences's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Coherus BioSciences in Xcout Intel
- 21 named people with titles, LinkedIn and board committees
- 4 funding rounds with the investors in each, and who they co-invest with
- Weekly hiring history and the mix of roles behind it
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access